Cambridge Healthtech Institute’s 3rd Annual

Ubiquitin-Induced Targeted Protein Degradation

Optimizing PROTACs and Small Molecule Degraders for Pursuing Undruggable Targets

April 14-15, 2020



The ubiquitin-proteasome system (UPS) is a well-controlled, selective mechanism for intracellular protein degradation and turnover, and acts as a key regulator in cancer, CNS, and other diseases. Over the past few years, a new generation of inhibitors and activators have been developed for disrupting protein-protein interactions and for hijacking the UPS for protein degradation. Proteolysis-targeting chimeric molecules (PROTACs), molecular glues, and other chemical entities are being developed for targeted protein degradation and have potential to seek out previously “undruggable” protein targets for drug discovery and therapeutic applications. However, some challenges do exist in terms of stability, biodistribution, and penetration of these molecules in vivo. The conference on Ubiquitin-Induced Targeted Protein Degradation will bring together experts who can discuss the potential, as well as the challenges underlying targeted protein degradation as a new approach for therapeutic intervention.


Preliminary Agenda

ASSAYS & MODELS FOR STUDYING DEGRADATION & TARGET SPECIFICITY

Use of Tip60 PROTACs in Cereblon-Knockin Mice

Wayne W. Hancock, MD, PhD, Professor, Pathology and Chief of Transplant Immunology, Children’s Hospital of Philadelphia and University of Pennsylvania

Chemical Tools to Evaluate E3: (Neo)Substrate Pairs

Alexander Statsyuk, PhD, Assistant Professor, Department of Pharmacological and Pharmaceutical Sciences, University of Houston

Engineered Ubiquitin Variants as Tools to Find Small Molecules Targeting Ubiquitin Enzymes

Jacky Chung, PhD, Scientist, Laboratory of Dr. Sachdev Sidhu, Donnelly Center, University of Toronto

Computational Exploration of Novel Drug Targets, Modalities and Design

Yuan Wang, PhD, Senior Principal Scientist, Head of TPD Data Science, UCB Pharma

DESIGN & OPTIMIZATION OF DEGRADERS AND INHIBITORS

ADME Properties of PROTACs and Oral Bioavailability Improvement Strategies

Upendra Dahal, PhD, Senior Scientist, Pharmacokinetics and Drug Metabolism, Amgen, Inc.

Target Engagement and Protein Degradation: Lessons Learned and Future Applications

Denise Field, PhD, Senior Scientist, I&I Chemistry and Chemical Biology, Pfizer Inc.

TARGETED PROTEIN DEGRADATION FOR ONCOLOGY

Targeted Degradation of Bromodomain-Containing Proteins for Cancer Therapy

Murali Ramachandra, PhD, CSO, Aurigene Discovery Technologies Limited

Ubiquitin-Mediated Small Molecule-Induced Target Elimination (uSMITE) for Cancer

Michael Plewe, PhD, Vice President, Medicinal Chemistry, Cullgen, Inc.

A Modular PROTAC Design for Target Destruction Using Single Amino Acid-Based Degradation Signal

Hai Rao, PhD, Professor, Molecular Medicine, University of Texas Health

TARGETED KINASE DEGRADATION STRATEGIES

Molecular Mechanisms of Small Molecule Mediated Ubiquitin Ligase Targeting

Eric Fischer, PhD, Assistant Professor, Cancer Biology/Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute/Harvard Medical School

Targeting Focal Adhesion Kinase with PROTACs: From Tool to in Vivo

Joao Nunes, PhD, Investigator, Protein Degradation Group, Medicinal Science and Technology, GSK Medicine Research Centre

New Activities for Cereblon Modulators

Philip Chamberlain, DPhil, Executive Director, Structural and Chemical Biology, Celgene

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated
2019/10/31
Agenda,Sponsor updated